Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Huang

Showing results (121-130 of 126) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 126 results.
Medrxiv : the Preprint Server for Health Sciences|September 30, 2020
Deep Immune Profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19Laura Vella, Josephine R Giles, Amy E Baxter, et al.
Science (New York, N.Y.)|July 17, 2020
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implicationsDivij Mathew, Josephine R Giles, Amy E Baxter, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventionsDivij Mathew, Josephine R Giles, Amy E Baxter, et al.
Cancer Research|September 24, 2025
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated CancersMichael Hulse, Min Wang, Chaoyi Xu, et al.
Science Immunology|March 3, 2021
Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19Laura A Vella, Josephine R Giles, Amy E Baxter, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Pageof 13

Showing results (121-130 of 126) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 126 results.
Medrxiv : the Preprint Server for Health Sciences|September 30, 2020
Deep Immune Profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19Laura Vella, Josephine R Giles, Amy E Baxter, et al.
Science (New York, N.Y.)|July 17, 2020
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implicationsDivij Mathew, Josephine R Giles, Amy E Baxter, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventionsDivij Mathew, Josephine R Giles, Amy E Baxter, et al.
Cancer Research|September 24, 2025
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated CancersMichael Hulse, Min Wang, Chaoyi Xu, et al.
Science Immunology|March 3, 2021
Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19Laura A Vella, Josephine R Giles, Amy E Baxter, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Pageof 13